Nov 2021 Articles

Articles
Prevalence and Significance of Risk Enhancing Biomarkers in the United States Population at Intermediate Risk for Atherosclerotic Disease; Risk Enhancing Factors in Intermediate Risk for ASCVD
Gloria L. Vega, Jijia Wang, Scott M. Grundy
Journal:
J Clin Lipidol

First published: November 30, 2021 DOI: 10.1016/j.jacl.2021.11.009
View
- Share
Articles
Statin Therapy in Very Old Patients: Lights and Shadows
Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M, et al.
Journal:
Front Cardiovasc Med

First published: November 29, 2021 DOI: 10.3389/fcvm.2021.779044
View
- Share
Articles
Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future
Catapano AL, Ray KK, Tokgözoglu L
Journal:
Atherosclerosis

First published: November 25, 2021 DOI: 10.1016/j.atherosclerosis.2021.11.021
View
- Share
Articles
Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content
Marston NA, Giugliano RP, Melloni GEM, et al.
Journal:
JAMA Cardiol

First published: November 13, 2021 DOI: 10.1001/jamacardio.2021.5083
View
- Share
Articles
Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort
Mortensen MB, Nordestgaard BG
Journal:
Lancet

First published: November 10, 2021 DOI: 10.1016/S0140-6736(20)32233-9
View
- Share
Articles
Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study
Sánchez-Ramos A, Fernández-Labandera C, Vallejo-Vaz AJ, et al.
Journal:
Atherosclerosis

First published: November 10, 2021 DOI: 10.1016/j.atherosclerosis.2021.11.007
View
- Share
Articles
Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction
McKinley EC, Bittner VA, Brown TM, et al.
Journal:
J Clin Lipidol

First published: November 7, 2021 DOI: 10.1016/j.jacl.2021.11.001
View
- Share
Articles
Familial Hypercholesterolemia: JACC Focus Seminar
Julia Brandts, Kausik K Ray
Journal:
Journal of the American College of Cardiology

First published: November 2, 2021 DOI: 10.1016/j.jacc.2021.09.004
View
- Share
Articles
National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk
Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki
Journal:
J Clin Lipidol

First published: November 2, 2021 DOI: 10.1016/j.jacl.2019.10.014
View
- Share
Articles
Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit
Orringer CE, Blaha MJ, Stone NJ
Journal:
J Clin Lipidol

First published: November 1, 2021 DOI: 10.1016/j.jacl.2021.09.052
View
- Share

Nov 2021 Articles

Articles

Prevalence and Significance of Risk Enhancing Biomarkers in the United States Population at Intermediate Risk for Atherosclerotic Disease; Risk Enhancing Factors in Intermediate Risk for ASCVD

Gloria L. Vega, Jijia Wang, Scott M. Grundy

Articles

Statin Therapy in Very Old Patients: Lights and Shadows

Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M, et al.

Articles

Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future

Catapano AL, Ray KK, Tokgözoglu L

Articles

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content

Marston NA, Giugliano RP, Melloni GEM, et al.

Articles

Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort

Mortensen MB, Nordestgaard BG

Articles

Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study

Sánchez-Ramos A, Fernández-Labandera C, Vallejo-Vaz AJ, et al.

Articles

Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction

McKinley EC, Bittner VA, Brown TM, et al.

Articles

Familial Hypercholesterolemia: JACC Focus Seminar

Julia Brandts, Kausik K Ray

Articles

National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk

Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki

Articles

Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit

Orringer CE, Blaha MJ, Stone NJ

Articles

Prevalence and Significance of Risk Enhancing Biomarkers in the United States Population at Intermediate Risk for Atherosclerotic Disease; Risk Enhancing Factors in Intermediate Risk for ASCVD

Gloria L. Vega, Jijia Wang, Scott M. Grundy

Share

Articles

Statin Therapy in Very Old Patients: Lights and Shadows

Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M, et al.

Share

Articles

Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future

Catapano AL, Ray KK, Tokgözoglu L

Share

Articles

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content

Marston NA, Giugliano RP, Melloni GEM, et al.

Share

Articles

Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort

Mortensen MB, Nordestgaard BG

Share

Articles

Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study

Sánchez-Ramos A, Fernández-Labandera C, Vallejo-Vaz AJ, et al.

Share

Articles

Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction

McKinley EC, Bittner VA, Brown TM, et al.

Share

Articles

Familial Hypercholesterolemia: JACC Focus Seminar

Julia Brandts, Kausik K Ray

Share

Articles

National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk

Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki

Share

Articles

Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit

Orringer CE, Blaha MJ, Stone NJ

Share